Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer : A phase III, randomised, multicentre trial (Ovaresist)
Background:Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC.Methods:Patients with PROC were randomised (2: 1) to chemotherapy (weekly paclitaxel 80 mg m -2 or four weekly pegylated liposomal do